Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial
Junichi Koike(Toho University Omori Medical Center), Shingo Kameoka(Tokyo Women's Medical University), Kazuhiro Sakamoto(Juntendo University), Michio Itabashi(Tokyo Women's Medical University), Yoshihisa Saida(Toho University Ohashi Medical Center), Masayuki Hisada(Tokyo Medical University), Kimihiko Funahashi(Toho University Omori Medical Center), Takeshi Yamada(Nippon Medical School), Hirotoshi Hasegawa(Tokyo Dental College Ichikawa General Hospital), Hideyuki Ishida(Tokyo Medical and Dental University), Keiichiro Ishibashi(Saitama Medical University), Kenji Katsumata(Tokyo Medical University), Shimpei Ogawa(Tokyo Women's Medical University), Toshiyuki Enomoto(Fukuoka University), Hayato Kan(Nippon Medical School), Hajime Yokomizo(Tokyo Women's Medical University Adachi Medical Center), Takumi Ochiai, Kazuhiko Yoshimatsu(Tokyo Women's Medical University Adachi Medical Center), Hiroyuki Shiokawa(Toho University), Keiji Koda(Teikyo University Chiba Medical Center)
Cited by 50
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2011|713
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
|International Journal of Clinical Oncology|2015|600
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer
|International Journal of Clinical Oncology|2021|157